BEYOND AIR INC (XAIR)
US08862L1035 - Common Stock
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants
GARDEN CITY, N.Y., March 20, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device...
Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024
Commercial demand for LungFit® PH increasing; manufacturing of upgraded devices is ramping up to meet growing demand PMA supplement for the expansion of...
Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast
Call scheduled for Monday, February 12th at 4:30 pm Eastern Time...
Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors
No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts per million (PPM) ...
Beyond Air CEO buys shares worth about $127k - filing (NASDAQ:XAIR)
Beyond Air CEO Steven Lisi purchases nearly $127k worth of the company's shares, bringing his total holdings to about 1.5 million shares.
Beyond Air director Robert Carey purchases 1.2M common shares (NASDAQ:XAIR)
Beyond Air director Robert Carey purchased 1.2M common shares at $1.635/share, investing around $1.96M.
Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference
GARDEN CITY, N.Y., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device...
Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024
Provides fiscal year 2025 revenue guidance of $12 - $16 million US pilot trial of LungFit® PRO to treat viral community acquired pneumonia (VCAP) underway...
Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
First-in-human Phase 1 study demonstrates early clinical proof of concept Positive clinical biomarker data demonstrate evidence of immune system...
Beyond Air® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast
Call scheduled for Monday, November 13th at 4:30 pm Eastern Time...
Beyond Air® To Participate in the Truist Securities BioPharma Symposium
GARDEN CITY, N.Y., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device...
Beyond Cancer™ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice
UNO therapy results in a more immunogenic tumor microenvironment (TME) as well as a systemic response that overcomes anti-PD-1 resistance ...
Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
50,000 or 100,000 ppm UNO alone or in combination with anti-mCTLA-4 more than tripled antigen specific central memory T-cell response versus anti-mCTLA-4...
Beyond Air receives Innovative Technology contract from Vizient (NASDAQ:XAIR)
Beyond Air receives Innovative Technology contract from Vizient for LungFit PH system, enhancing healthcare performance with cutting-edge technology.
Beyond Air® Receives Innovative Technology Contract from Vizient for LungFit®PH
Contract awarded for products that bring improvement to health care industry...
Beyond Cancer™ Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is...
Beyond Air® To Participate in the Roth MKM 2023 Healthcare Opportunities Conference
GARDEN CITY, N.Y., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd.), today announced that the Company will present a corporate overview and participate in one-on-one meetings at the Roth MKM 2023 Healthcare Opportunities Conference being held on Thursday, October 12, 2023 in New York City, NY.